Should de-SPAC’d companies consider buying back their shares rather than making offers for their warrants? Abacus Life (NASDAQ:ABL) believes the answer is yes.
This week, we catch up with with Abacus Life Chairman and CEO Jay Jackson. He tells us why he thinks his company’s stock has managed to perform well in the six months since closing its SPAC combination with East Resources and why he has taken the unorthodox decision to buy back shares rather than deal immediately Abacus Life’s warrant overhang.
We also discuss the future of the company’s business of acquiring life insurance policies and how it is now engaging directly with policy holders and the insurance issuers as clients. With many years at work investing in such policies, what has the data told Abacus Life about longevity and long-term health itself?
Give it a listen
Terms Tracker for the Week Ending May 3, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. The big news this week was that SPACs finally had a new IPO price with Churchill Capital Corp. IX’s $250 million offering on Thursday. SPACs...
Real estate marketplace Opendoor (NASDAQ:OPEN) is poised to be the latest de-SPAC to take a double-digit jump on earnings as it heads towards the weekend up +10%, having spiked as high as +27% earlier in the day. The movement comes as the former Social Capital II target reported progress towards profitability despite a high rates...
At the SPAC of Dawn Coinbase (NASDAQ:COIN) notched a surprise profit of over $1.5 billion in the first quarter of 2024, well exceeding estimates, demonstrating the powerful effect of publicly traded ETFs have had on crypto marketplaces since the start of the year. The result has pushed the company to bump up its own guidance...
Online casino and sports company Rush Street (NYSE:RSI) is up +18.4% in trading today on the back of a solid first quarter earnings release, bringing the company’s stock to its highest price since the second half of 2022 (currently $7.60). This makes it the latest in a line of 2020 and 2021 de-SPACs that have...
Mountain Crest V (NASDAQ:MCAG) broke a long dealmaking silence by SPACs this morning, albeit with a non-binding agreement to combine with Seoul-based diagnostic biotech firm CUBEBIO. The term sheet would give the company a $620 million pre-transaction equity value and help accelerate the rollout of CUBEBIO’s CEED-NOVUS cancer screening kit products. The company signed an...